Aspira Women's Health Inc. (AWHL) — SEC Filings

Latest SEC filings for Aspira Women's Health Inc. (AWHL), explained in plain English.

Sentiment Overview: 4 bearish, 46 neutral

Recent Filings (50)

• AWHL Files 2025 10-K; Financial Details Not in Metadata — 10-K · 2026-04-01T15:46:13-04:00 [neutral] Risk: undetermined
  Aspira Women's Health Inc. (AWHL) filed its 2025 10-K report with the SEC on April 1, 2026, under CIK 0000926617, covering the fiscal year ended December 31, 20
• 8-K Filing — 8-K · 2025-12-31T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-12-23T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-12-22T00:00:00.000Z [neutral]
• 10-Q Filing — 10-Q · 2025-11-14T00:00:00.000Z [neutral]
• 8-K/A Filing — 8-K/A · 2025-11-03T00:00:00.000Z [neutral]
• Aspira Women's Health Files S-1/A Amendment — S-1/A · 2025-10-20T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an amendment (S-1/A) on October 20, 2025, for its registration statement. The company, formerly known as Vermillion, Inc. and C
• Aspira Women's Health Files 8-K — 8-K · 2025-10-15T00:00:00.000Z [neutral] Risk: low
  On October 14, 2025, Aspira Women's Health Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 12117 Be
• Aspira Women's Health Files S-1 for Public Offering — S-1 · 2025-09-30T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an S-1 registration statement on September 30, 2025, to register securities under the Securities Act of 1933. The company, form
• Aspira Women's Health Files 8-K on Agreements and Equity Sales — 8-K · 2025-09-25T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an 8-K on September 25, 2025, reporting on events that occurred on September 19, 2025. The filing indicates an entry into a mat
• Aspira Women's Health Files 8-K — 8-K · 2025-09-18T00:00:00.000Z [neutral] Risk: medium
  On September 16, 2025, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securi
• Aspira Women's Health: Director Departs, New Director Appointed — 8-K · 2025-09-03T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. announced on September 2, 2025, the departure of Director Dr. Jonathan M. Gelfond and the appointment of Dr. David L. Smith as a new
• Aspira Women's Health Files Q2 2025 10-Q — 10-Q · 2025-08-13T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed its 10-Q for the period ending June 30, 2025. The filing details financial performance and operational updates for the second q
• Aspira Women's Health Inc. Reports Board and Executive Changes — 8-K · 2025-07-15T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on July 11, 2025, changes related to its board of directors and executive compensation. The filing details the departure of
• Aspira Women's Health Files 8-K — 8-K · 2025-06-11T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed an 8-K on June 11, 2025, reporting other events and financial statements. The filing details the company's corporate structure
• Aspira Women's Health Files 8-K on Shareholder Vote Matters — 8-K · 2025-06-04T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of its security holders. The filing details corporate actions
• Aspira Women's Health Files Q1 2025 10-Q — 10-Q · 2025-05-19T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Vermillion, Inc., is involved in in vitro & in vi
• Aspira Women's Health Files S-1/A Update — S-1/A · 2025-05-06T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed an S-1/A on May 6, 2025, to update its registration statement. The company, formerly known as Vermillion, Inc., Ciphergen Biosy
• Aspira Women's Health Files S-1/A Amendment — S-1/A · 2025-05-01T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an S-1/A amendment on May 1, 2025, related to its public offering. The company, formerly known as Vermillion, Inc. and Cipherge
• Aspira Women's Health Faces Delisting Concerns — 8-K · 2025-04-16T00:00:00.000Z [bearish] Risk: high
  Aspira Women's Health Inc. filed an 8-K on April 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filin
• Aspira Women's Health Inc. DEF 14A Filing — DEF 14A · 2025-04-11T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed a DEF 14A on April 11, 2025, detailing executive compensation and board member information for the fiscal year ending December
• Aspira Women's Health Reports Material Agreements & Officer Changes — 8-K · 2025-04-08T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an 8-K on April 8, 2025, reporting on several key events that occurred on April 2, 2025. These include entering into a material
• Aspira Women's Health Inc. Reports Board and Executive Changes — 8-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on March 27, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
• Aspira Women's Health Files 2024 10-K — 10-K · 2025-03-27T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Vermilli
• Aspira Women's Health Inc. Reports Director and Officer Changes — 8-K · 2025-03-25T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on March 21, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
• Aspira Women's Health Reports Officer and Director Changes — 8-K · 2025-03-19T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an 8-K on March 19, 2025, reporting changes as of March 15, 2025. The filing pertains to the departure of directors or certain
• Aspira Women's Health Files 8-K for Equity Sale — 8-K · 2025-03-11T00:00:00.000Z [neutral] Risk: medium
  On March 5, 2025, Aspira Women's Health Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, forme
• Aspira Women's Health Faces Delisting Notice — 8-K · 2025-02-14T00:00:00.000Z [bearish] Risk: high
  Aspira Women's Health Inc. filed an 8-K on February 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of F
• Aspira Women's Health Files S-1/A Update — S-1/A · 2025-02-11T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an S-1/A on February 11, 2025, to update its registration statement. The company, formerly known as Vermillion, Inc., is in the
• Aspira Women's Health Appoints New Directors, Adjusts Executive Pay — 8-K · 2025-02-10T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on February 5, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two ne
• Aspira Women's Health Inc. Reports Board and Officer Changes — 8-K · 2025-01-31T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on January 28, 2025, a change in its board of directors. Specifically, the company reported the departure of certain office
• Aspira Women's Health Files 8-K — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  On January 13, 2025, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibit
• Aspira Women's Health Files S-1 — S-1 · 2025-01-08T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed an S-1 registration statement on January 8, 2025, to register securities under the Securities Act of 1933. The company, formerl
• Aspira Women's Health Inc. Reports Board and Officer Changes — 8-K · 2025-01-07T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on January 6, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officer
• Aspira Women's Health Faces Delisting Notice — 8-K · 2024-12-31T00:00:00.000Z [bearish] Risk: high
  Aspira Women's Health Inc. filed an 8-K on December 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was fo
• Aspira Women's Health Inc. Reports Board and Compensation Changes — 8-K · 2024-12-16T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on December 16, 2024, changes in its board of directors and executive compensation arrangements. The filing details the dep
• Aspira Women's Health Files Q3 2024 10-Q — 10-Q · 2024-11-19T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed a 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the fiscal ye
• Aspira Women's Health Files 8-K on Financials — 8-K · 2024-11-14T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed an 8-K on November 14, 2024, to report on its results of operations and financial condition. The filing includes financial stat
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2024-10-29T00:00:00.000Z [neutral]
• Aspira Women's Health Files 8-K — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  On October 24, 2024, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine updat
• Aspira Women's Health Files 8-K — 8-K · 2024-10-23T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed an 8-K on October 23, 2024, reporting other events and financial statements. The company, formerly known as Vermillion, Inc., C
• Aspira Women's Health Faces Nasdaq Delisting Warning — 8-K · 2024-10-18T00:00:00.000Z [bearish] Risk: high
  Aspira Women's Health Inc. received a notice on October 17, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Marke
• Aspira Women's Health Files 8-K — 8-K · 2024-09-13T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed an 8-K on September 13, 2024, reporting an event on September 9, 2024. The filing primarily concerns financial statements and e
• Aspira Women's Health Files Q2 10-Q, Details Stock Offerings — 10-Q · 2024-08-13T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities, includ
• Aspira Women's Health Files 8-K on Financials — 8-K · 2024-08-12T00:00:00.000Z [neutral] Risk: low
  Aspira Women's Health Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Aspira Women's Health Files 8-K with Material Agreement — 8-K · 2024-08-02T00:00:00.000Z [neutral] Risk: low
  On August 2, 2024, Aspira Women's Health Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, formerly know
• Aspira Women's Health Files 8-K with Material Agreement — 8-K · 2024-07-31T00:00:00.000Z [neutral] Risk: medium
  On July 31, 2024, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• Aspira Women's Health Appoints New CMO, Director — 8-K · 2024-07-29T00:00:00.000Z [neutral] Risk: medium
  Aspira Women's Health Inc. announced on July 25, 2024, the appointment of Dr. Michael J. Nally as Chief Medical Officer and the election of Ms. Karen L. King to
• Schuler Amends Aspira Women's Health Stake — SC 13D/A · 2024-07-11T00:00:00.000Z [neutral] Risk: medium
  Jack W. Schuler, through an amendment filed on July 11, 2024, has updated his beneficial ownership of Aspira Women's Health Inc. common stock. The filing indica